Biodexa Pharmaceuticals Plc (NASDAQ:BDRX – Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 189,600 shares, a growth of 183.8% from the March 31st total of 66,800 shares. Based on an average trading volume of 2,030,000 shares, the short-interest ratio is presently 0.1 days.
Biodexa Pharmaceuticals Trading Up 79.4 %
Biodexa Pharmaceuticals stock traded up $0.58 during trading on Friday, hitting $1.30. 70,155,596 shares of the company were exchanged, compared to its average volume of 311,676. The business’s 50 day moving average is $1.16 and its 200 day moving average is $2.20. Biodexa Pharmaceuticals has a 52 week low of $0.67 and a 52 week high of $21.38.
Analyst Upgrades and Downgrades
Separately, LADENBURG THALM/SH SH assumed coverage on Biodexa Pharmaceuticals in a research note on Thursday, February 8th. They set a “buy” rating and a $8.00 price target for the company.
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.
Further Reading
- Five stocks we like better than Biodexa Pharmaceuticals
- How to Capture the Benefits of Dividend Increases
- MarketBeat Week in Review – 4/22 – 4/26
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Stocks Leading the U.S. Agriculture Comeback
- Retail Stocks Investing, Explained
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Biodexa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodexa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
